Advanced search×

A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

Christos Hatzis, Lajos Pusztai, Vicente Valero, Daniel J Booser, Laura Esserman, Ana Lluch, Tatiana Vidaurre, Frankie Holmes, Eduardo Souchon, Hongkun Wang, Miguel Martin, José Cotrina, Henry Gomez, Rebekah Hubbard, J Ignacio Chacón, Jaime Ferrer-Lozano, Richard Dyer, Meredith Buxton, Yun Gong, Yun Wu, Nuhad Ibrahim, Eleni Andreopoulou, Naoto T Ueno, Kelly Hunt, Wei Yang, Arlene Nazario, Angela DeMichele, Joyce O'Shaughnessy, Gabriel N Hortobagyi, and W Fraser Symmans

JAMA 305(18):1873-81 (2011) PMID 21558518

Prediction of high probability of survival from standard cancer treatments is fundamental for individualized cancer treatment strategies.

DOI: 10.1001/jama.2011.593
Version: za2963e q8za3 q8zb1 q8zc2 q8zdd q8ze5 q8zf0 q8zg9

Similar articles you may find interesting…

  1. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer
    Takayuki Iwamoto, Giampaolo Bianchini, ... Naoto T Ueno

    Breast Cancer Res Treat 125(3):785-795 (2011) PMID 21153052

    We used Affymetrix GeneChips to analyze 82 tumor samples (25 T4d patients, and 57 T4a-c patients) of newly diagnosed breast cancers. Genes that were differentially expressed between the IBC and non-IBC specimens were identified using the t test, and differential expression of gene sets was assessed...
  2. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic br...
    Ugo U De Giorgi, Vicente V Valero, ... Massimo M Cristofanilli

    J Clin Oncol 27(20):3303-11 (2009) PMID 19451443

    In 102 evaluable patients, the median overall survival time was 14 months (range, 1 to > 41 months). Midtherapy CTC levels correlated with FDG-PET/CT response in 68 (67%) of 102 evaluable patients. In univariate analysis, midtherapy CTC counts and FDG-PET/CT response predicted overall survival (P <...